ADC — Initial data
2H 2026
2H 2026 : Anticipate POC data in humanized model of AMLSource filing
HURA biotech catalysts & pipeline
TUHURA BIOSCIENCES INC · Data as of 2026-09-08
Upcoming catalysts
IFx-2.0 — Interim data
2H 2026
2H 2026: Anticipate preliminary data from the Phase1b/2a study of IFx-2.0 as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)Source filing
IFx-2.0 — Regulatory decision
2H 2026
• 2H 2026: Expect to receive orphan drug designation in MCCSource filing
immune modulating ADC — Initial data
Q3 2026
• Q3 2026 : Anticipates first proof of concept in-vivo results from its lead immune modulating ADC.Source filing
TBS-2025 — Regulatory decision
2H 2026
• 2H 2026: Expect to receive orphan drug designation in AMLSource filing
VISTA — FDA meeting
H2 2026
In the second half, we anticipate receiving safe-to-proceed feedback from FDA and to initiating our Phase 1b/2 trial of VISTA in mut NPM1 r/r AML, initiating our in vivo POC studies for MDSC Inhibitors (Bi-specific antibody drug conjugates (ADCs)), potentially receiving orphan drug designation in Merkel cell carcinoma (MCC) for IFx-2.0, and potentially receiving orphan drug designation in AML for TBS-2025.Source filing
IFx-2.0 — Initial data
1H2027
• 1H2027: Expect preliminary results from IR study IFX-2.0 with Keytruda® for deep seated MCCSource filing
TBS-2025 — Initial data
1H 2027
• 1H 2027: Expect preliminary safety and response data for VISTA in mutated NMP1 r/r AMLSource filing
VISTA — Initial data
1H 2027
1H 2027: Expect preliminary safety and response data for VISTA in mutated NMP1 r/r AMLSource filing
IFx-2.0 — Topline data
H2 2027
We anticipate topline results from the Phase 3 accelerated approval trial of IFx-2.0 in the second half of 2027.Source filing
MDSC Inhibitors (Bi-specific antibody drug conjugates (ADCs)) — Conference presentation
2H 2026
• 2H 2026 : Presentations at key scientific meetingsSource filing